ArticleResuscitation plus2025
Design of the OverCool study: Lung-conservative liquid ventilation for the induction of Ultra-Rapid Cooling after Cardiac Arrest (OverCool).
Article in Resuscitation plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lung-cOnservative Liquid VEntilation for the Induction of Ultra-Rapid COOLing After Cardiac Arrest
Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling, a Prospective Non-interventional Cohort
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Does Time to Achieve a Targeted Body Temperature Matter for Survivors of Cardiac Arrest? A Systematic Review and Meta-Analysis.Critical care medicine · 2026Pooled it
- European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2025: post-resuscitation care.Intensive care medicine · 2025Guideline
- Hypothermia after Cardiac Arrest in Large Animals (HACA-LA): a randomized controlled experimental study.Intensive care medicine experimental · 2025Article
- Total liquid ventilation in a porcine model of severe acute respiratory distress syndrome using a new generation of liquid ventilator.Intensive care medicine experimental · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The therapeutic window within which induced hypothermia might be effective after cardiac arrest is still unknown. In animal cardiac arrest models, early induction and faster cooling are independently associated favorable outcome. However, induction of Ultra-Rapid Therapeutic Hypothermia (achieving core body temperature of 33.0 ± 0.5 °C within 60 min after the start of the procedure) still need to be evaluated in the human setting. Total liquid ventilation with temperature-controlled breathable liquids provided such rapid cooling (i.e. >15 °C/h cooling rate) in both small and large animals. This method was shown to improve neurological outcome in animals. A new medical device system, Vent2Cool, was developed for clinical use in the Intensive Care Unit to achieve ultra-rapid therapeutic hypothermia by total liquid ventilation to patients. Materials and methods: The non-blinded and single-arm OverCool pilot trial will evaluate the feasibility, cooling performance and safety of ultra-rapid therapeutic hypothermia by total liquid ventilation in 24 patients resuscitated after in- or out-of-hospital cardiac arrest. Inclusion criteria will include presumption to start ultra-rapid cooling procedure in the Intensive Care Unit within less than 120 min after resuscitation. The primary outcome will be the achievement of a core temperature of 33.0 ± 0.5 °C, as well as successful return to conventional gas ventilation within <60 min after procedure initiation. Secondary outcomes will include time to reach target temperature, vital status, systemic and pulmonary parameters and modified-Rankin Score at 28 days post- cardiac arrest. Conclusion: The OverCool study is a pilot study to validate performance and safety of ultra-rapid therapeutic hypothermia using total liquid ventilation for resuscitated cardiac arrest patients. Registration and authorization: NCT06798818. Authorized by the French "Agence nationale de sécurité du médicament et des produits de santé" and "Comité de Protection des Personnes" (Ethics Committee).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.